OTCPK:AMAR (USA) Also trade in: Germany

Amarillo Biosciences Inc

$ 0.35 0 (0%)
Volume: 0 Avg Vol (1m): 3,291
Market Cap $: 13.78 Mil Enterprise Value $: 13.21 Mil
P/E (TTM): 0.00 P/B: 25.00
Earnings Power Value -0.08
Net Current Asset Value 0.01
Tangible Book 0.01
Projected FCF -0.13
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5.8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 2.20
Cash-To-Debt range over the past 10 years
Min: 0, Med: 0.17, Max: 10000
Current: 2.2
0
10000
Equity-to-Asset 0.45
Equity-to-Asset range over the past 10 years
Min: -34.67, Med: -7.37, Max: 0.95
Current: 0.45
-34.67
0.95
Debt-to-Equity 0.86
Debt-to-Equity range over the past 10 years
Min: -12.42, Med: -0.76, Max: 26
Current: 0.86
-12.42
26
Debt-to-EBITDA -0.31
Debt-to-EBITDA range over the past 10 years
Min: -7.01, Med: -1.23, Max: -0.08
Current: -0.31
-7.01
-0.08
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.89
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 0.74%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -6160.00
Operating Margin range over the past 10 years
Min: -55500, Med: -2565.82, Max: -231.08
Current: -6160
-55500
-231.08
Net Margin % -6148.00
Net Margin range over the past 10 years
Min: -65100, Med: -1991.1, Max: 10120
Current: -6148
-65100
10120
ROE % -227.43
ROE range over the past 10 years
Min: -227.43, Med: -222.98, Max: -222.98
Current: -227.43
-227.43
-222.98
ROA % -98.82
ROA range over the past 10 years
Min: -1489.22, Med: -231.03, Max: 203.21
Current: -98.82
-1489.22
203.21
ROC (Joel Greenblatt) % -9058.82
ROC (Joel Greenblatt) range over the past 10 years
Min: -220400, Med: -6512.2, Max: 24000
Current: -9058.82
-220400
24000
3-Year Total EBITDA Growth Rate -36.70
N/A
3-Year EPS w/o NRI Growth Rate -10.10
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -10.1, Max: 56.3
Current: -10.1
0
56.3

» AMAR's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with OTCPK:AMAR

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare LSE:OKYO NAS:DARE OTCPK:BSTG TSXV:DVA XSAT:SYNACT OTCPK:CAPD AMEX:IBIO XPAR:ALBPS NAS:NVLN OTCPK:CLCS ASX:IMC ASX:1AD LSE:FAB XCNQ:PREV LSE:HEMO NAS:ACHV NAS:DFFN OSTO:CYXO OTCPK:MATN MIC:LIFE
Traded in other countries FZX.Germany
Address 4134 Business Park Drive, Amarillo, TX, USA, 79110-4225
Amarillo Biosciences Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a proprietary low dose oral form.

Ratios

Current vs industry vs history
PB Ratio 25.00
PB Ratio range over the past 10 years
Min: 8.1, Med: 15.45, Max: 26.82
Current: 25
8.1
26.82
EV-to-EBIT -8.66
EV-to-EBIT range over the past 10 years
Min: -19.6, Med: -1.3, Max: 12
Current: -8.66
-19.6
12
EV-to-EBITDA -8.66
EV-to-EBITDA range over the past 10 years
Min: -19.6, Med: -1.3, Max: 12
Current: -8.66
-19.6
12
EV-to-Revenue 533.15
EV-to-Revenue range over the past 10 years
Min: 1.5, Med: 29.3, Max: 1369.8
Current: 533.15
1.5
1369.8
Current Ratio 1.59
Current Ratio range over the past 10 years
Min: 0.01, Med: 0.12, Max: 32.51
Current: 1.59
0.01
32.51
Quick Ratio 1.58
Quick Ratio range over the past 10 years
Min: 0.01, Med: 0.09, Max: 32.51
Current: 1.58
0.01
32.51
Days Inventory 26.28
Days Inventory range over the past 10 years
Min: 26.28, Med: 90.08, Max: 115.58
Current: 26.28
26.28
115.58
Days Payable 2.00
Days Payable range over the past 10 years
Min: 2, Med: 4478.27, Max: 74003.75
Current: 2
2
74003.75

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -21.00
3-Year Share Buyback Rate range over the past 10 years
Min: -81.7, Med: -21.7, Max: -0.8
Current: -21
-81.7
-0.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 35.00
Price-to-Tangible-Book range over the past 10 years
Min: 2.01, Med: 4.56, Max: 166.3
Current: 35
2.01
166.3
Earnings Yield (Joel Greenblatt) % -11.57
Earnings Yield (Greenblatt) range over the past 10 years
Min: -1198.6, Med: -60, Max: 37
Current: -11.57
-1198.6
37

More Statistics

Revenue (TTM) (Mil) $ 0.03
EPS (TTM) $ -0.05
Beta -0.16
Volatility % 95.46
52-Week Range $ 0.12 - 0.61
Shares Outstanding (Mil) 39.66

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N